Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YM150 plus standard therapy in secondary prevention after acute coronary syndrome
2008-005972-29Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of darexaban in acute coronary syndrome (ACS) and Ischemic vascular event (IVE) (4 arms), sponsored by Astellas Pharma. Primary endpoint: Major and clinically relevant non-major bleeding at 6 months. Started Jul 2009; status: completed.
02
Drugs
darexaban
03
Conditions
acute coronary syndrome (ACS)Ischemic vascular event (IVE)
Beyond the preview
Go deeper on 2008-005972-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005972-29.